RANDOMIZED EFFICACY AND SAFETY TRIAL WITH ORAL S 44819 AFTER RECENT ISCHEMIC CEREBRAL EVENT INTERNATIONAL, MULTI-CENTRE, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY
- Registry ID
- CL2-44819-004
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- SERVIER CANADA INC
- Start date
- 2017-07-29
- Last update
- 2016-08-03
Conditions
- STROKE
- ISCHEMIC ATTACK AND MINOR STROKE
Related clinical trials
- Prospective Evaluation of Atrial Fibrillation-Related Stroke Patients in Rehabilitation Program (PEARL), an Observational Cohort Study
- NUANCE-ICAD: EFFECT OF GENOTYPE-GUIDED ORAL P2Y12 INHIBITOR SELECTION VS CONVENTIONAL CLOPIDOGREL THERAPY IN SYMPTOMATIC INTRACRANIAL ATHEROSCLEROTIC DISEASE: A PILOT PROSPECTIVE, RANDOMIZED, OPEN-LABEL, BLINDED-ENDPOINT (PROBE) MULTI-CENTRE STUDY
- THROMBOLYSIS DOMAIN (ACT WHEN) A MULTI-FACTORIAL, MULTI-ARM, MULTI-STAGE, RANDOMISED,
GLOBAL ADAPTIVE PLATFORM TRIAL FOR STROKE (ACT-GLOBAL)
- FOCAL CEREBRAL ARTERIOPATHY STEROID (FOCAS) TRIAL
- A MULTICENTER, PROSPECTIVE, RANDOMIZED, OPEN LABEL, BLINDED-ENDPOINT, CONTROLLED, SINGLE-DOSE TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF NONO-42 IN PARTICIPANTS WITH ACUTE ISCHEMIC STROKE SELECTED FOR THROMBOLYSIS WITH OR WITHOUT ENDOVASCULAR THROMBECTOMY (ACT-42 TRIAL)
- A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND SAFETY OF MILVEXIAN, AN ORAL FACTOR XIA INHIBITOR, FOR STROKE PREVENTION AFTER AN ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK
View on source registry